New compounds, pharmaceutical compositions and uses thereof
申请人:ROTH Gerald Juergen
公开号:US20120214782A1
公开(公告)日:2012-08-23
The invention relates to new compounds of the formula I
to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
Direct and selective synthesis of N,N-dimethylated amines from nitriles using methanol as C1 building blocks is reported using an air- and moisture-stable ruthenium complex. Following this process, various aromatic as well as aliphatic nitriles were converted to the corresponding N-methylated amines. Interestingly, tandem C-methylation as well as N-methylation was achieved by introducing multiple methyl
[EN] PYRAZOLE DERIVATIVES AS SGC STIMULATORS<br/>[FR] DÉRIVÉS DE PYRAZOLE UTILISÉS COMME STIMULATEURS DE SGC
申请人:IRONWOOD PHARMACEUTICALS INC
公开号:WO2016044447A1
公开(公告)日:2016-03-24
There are described imidazole and pyrazole derivatives which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.
[EN] CYCLOBUTENEDIONE DERIVATIVES<br/>[FR] DÉRIVÉS DE CYCLOBUTÈNE-DIONE
申请人:PFIZER LTD
公开号:WO2010131145A1
公开(公告)日:2010-11-18
The present invention relates to compounds of the formula (I): to pharmaceutically acceptable salts therefore and to pharmaceutically acceptable solvates of said compounds and salts, wherein the substituents are defined herein; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly inflammatory conditions.
The invention concerns benzamide compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R
1
, ring A, n, R
3
, and R
4
are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4, and/or EphA2 and/or Src kinases.